reptides › growth hormone › cjc-1295

cjc-1295

growth hormone without injecting growth hormone. tells your pituitary to make its own. paired with ipamorelin.

tier A · growth hormone · PCAC '24 503A excluded

verdict

tells the pituitary to make its own GH through the GHRH receptor. paired with ipamorelin. DAC vs no-DAC is the live argument.

if you're asking about DAC vs no-DAC — the DAC version pushes GH up and keeps it up by binding albumin and extending half-life. the no-DAC version preserves more of the natural pulse pattern, especially when stacked with ipamorelin. the community voted with its feet against DAC. fluid retention, likely receptor desensitization from continuous (vs pulsatile) signaling. clinic protocols mostly run the no-DAC version now.

if you're asking what the data actually shows — Teichman 2006: single-dose GH 2-10x baseline for six or more days, IGF-1 1.5-3x baseline for 9-11 days. that's published phase 1 PK/PD. it's real. no phase 3 ever ran, so long-term efficacy and safety data are not what you'd want them to be. the newer literature is mostly anti-doping metabolism work. that pattern usually means a compound is better established as a doping target than as a therapeutic.

if you came in via the clinic CJC-1295 + ipamorelin protocol — the receptor logic is clean and well-characterized. GHRH receptor plus ghrelin receptor through separate pathways produces a larger pulse than either alone. user-reported wins (sleep, body comp) are consistent. the missing piece is the same as ipamorelin's. no FDA approval, and after Oct 29, 2024, no 503A pathway for the ipamorelin half. the ceiling on this protocol is regulatory, not pharmacological.

based on published evidence and disclosed clinical practice. not medical advice.

why A-tier

a synthetic GHRH analog engineered by ConjuChem to have a dramatically extended half-life, achieved by covalent binding to endogenous albumin via a drug affinity complex (DAC). comes in two forms: with DAC (6-8 day half-life, single weekly dose) and without DAC (short-acting, "Mod GRF 1-29," used in stacked protocols). the GHRH-receptor agonism mechanism is well-characterized, but a phase 2 HIV-lipodystrophy trial was discontinued after a patient death (attending physician concluded unrelated). A-tier based on mechanism plausibility and consistent user reports from peptide clinics, held back from S by the absence of a completed clinical program and no FDA approval.

the core tension

It was designed as the FDA-approved alternative to HGH. ConjuChem's program ended before approval, but the phase 1 pharmacology is real. The clinical-development gap is just as real. Compounding pharmacies and peptide clinics picked it up anyway, which explains the market gravity without turning that market into an approval-grade evidence base.

what it is

a modified GHRH (1-29) with four amino acid substitutions that block protease degradation. it comes in two forms. with DAC (drug affinity complex, a linker that covalently binds your own albumin), the half-life is 6-8 days. without DAC, also sold as Modified GRF 1-29, it clears in about 30 minutes. neither has FDA approval. they are not interchangeable.

what it does

activates the GHRH receptor on pituitary somatotrophs. the pituitary makes more growth hormone and releases it. Teichman 2006: single-dose GH 2-10x baseline for six or more days, IGF-1 1.5-3x baseline for 9-11 days. the DAC version drives GH up and keeps it there. the no-DAC version preserves more of the natural pulse pattern, especially when stacked with ipamorelin.

origin

ConjuChem Biotechnologies, a Montreal biotech, built CJC-1295 in the early 2000s. phase 1 data was strong. in July 2006, a phase 2 subject died of myocardial infarction shortly after a dosing visit. autopsy: asymptomatic coronary disease, plaque rupture. death assessed as not drug-related. ConjuChem suspended the program anyway and never came back. ConjuChem never commercialized CJC-1295. the compound moved into peptide clinics and the gray market.

why researchers are interested

CJC-1295 + ipamorelin is the most common peptide-clinic GH-axis stack, full stop. the mechanism is clean. GHRH receptor plus ghrelin receptor hit the same somatotrophs through separate pathways and produce a bigger pulse than either alone. sleep is the most consistent subjective win. body composition shifts over 3-6 months. not dramatic. not nothing.

does it work

probably, in the way the data supports. phase 1 PK and PD claims are published and real. the mechanism is well-characterized. long-term efficacy and safety are not. no phase 3 ever ran. the community voted with its feet against the DAC version. fluid retention, likely receptor desensitization from continuous (vs pulsatile) signaling. the newer literature is mostly anti-doping metabolism work, not new efficacy trials. that usually means a compound is better established as a doping target than as a therapeutic. A-tier on mechanism and phase 1 data. the missing FDA approval is the ceiling.

claims vs the data

  • raises GH and IGF-1 significantly — supported — Teichman et al. 2006: 2-10x GH elevation for 6+ days, 1.5-3x IGF-1 elevation for 9-11 days per single dose.
  • stimulates natural pulsatile GH release — contradicted — the with-DAC version produces sustained, not pulsatile, GH elevation. mod GRF 1-29 (no DAC) preserves some pulsatility.
  • safer than exogenous HGH — partially true — uses body's negative feedback (somatostatin can still suppress). but the DAC version overrides much of the natural control. short-acting mod GRF preserves control better.
  • synergizes with ipamorelin — supported — GHRH + GHS pathways activate independently. combined effect is larger than either alone. mechanistic basis is well-documented, though controlled human combination trial is limited.
  • FDA-approved — contradicted — no FDA approval. classified as an Investigational New Drug. never completed a successful phase 2 program.
  • one weekly injection for months-long GH elevation — supported — this is literally the pharmacokinetic design. IGF-1 remained elevated up to 28 days after repeated dosing in human trials.

key facts

  • molecular formula: C₁₃₅H₂₆₃N₅₁O₃₈
  • molecular weight: 3368.7 g/mol (with DAC); ~3367 g/mol (no DAC)
  • amino acids: 30 (modified GHRH 1-29 + DAC linker)
  • half-life: ~6-8 days (with DAC); ~30 min (no DAC / Mod GRF 1-29)
  • type: long-acting GHRH analog
  • CAS: 863288-34-0 (with DAC)
  • 6-8 days half-life (with DAC)
  • 2–10x GH increase, single injection
  • 4 aa substitutions vs native GHRH
  • discontinued phase 2 HIV lipo program

frequently asked questions

What is CJC-1295?

CJC-1295 is a modified growth hormone-releasing hormone (GHRH) analog. It exists in two forms: CJC-1295 with DAC (drug affinity complex, long-acting ~8 day half-life) and CJC-1295 without DAC (also called modified GRF 1-29, short-acting ~30 minute half-life). Both stimulate GH release via the GHRH receptor.

What does CJC-1295 do?

CJC-1295 stimulates natural GH release from the pituitary via GHRH receptor activation. Community users commonly pair it with ipamorelin to combine GHRH and GHRP mechanisms for synergistic GH pulses. Reported effects include improved sleep, recovery, body composition, and skin quality over months of consistent use.

How is CJC-1295 typically administered?

CJC-1295 appears in injectable research-peptide contexts. The key evidence distinction is not the injection itself but the form: no-DAC is short acting, while DAC is long acting and produces more sustained GH/IGF-1 exposure. There is no FDA-approved dosing framework for either form.

What are the side effects of CJC-1295?

Common side effects include injection-site reactions, mild flushing, transient headache, and occasional fluid retention. The long-acting DAC version has more concerns due to sustained GH/IGF-1 elevation rather than pulsatile stimulation; community preference has shifted toward the no-DAC version accordingly.

Is CJC-1295 FDA approved?

No. CJC-1295 is not FDA-approved for any indication. Early clinical development did not progress to approval. It is sold as a research chemical and is prohibited under WADA for competitive athletes.

How much does CJC-1295 cost?

CJC-1295 is not a prescription drug and has no clinical retail price. On the research-chemical market it is inexpensive, with DAC versions generally priced above the no-DAC version. Hormone clinics have sold CJC-1295/ipamorelin blends as monthly packages.

related peptides

  • cjc+ipa blend — the standard GH stack, both in one vial
  • ipamorelin — GHRP stacking partner
  • sermorelin — shorter-acting GHRH predecessor
  • tesamorelin — FDA-approved GHRH analog (HIV only)
  • hgh — the direct GH version it substitutes for

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.